Trial Profile
Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Acronyms EOS-1
- Sponsors Dr Falk Pharma
- 23 May 2021 Results of a subset analysis assessing the impact of BOT 1mg BID versus placebo for changing the esophageal distensibility during a 6-week induction of remission treatment. presented at the Digestive Disease Week 2021
- 25 Mar 2019 Results assessing the effectiveness and tolerability of a budesonide orodispersible tablet published in the Gastroenterology.
- 01 Nov 2017 Primary endpoint has been met. (Rate of clinico-pathological remission) as per results presented at the 25th United European Gastroenterology Week